Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Old Is New Again: Bristol Cancer Plans Re-Emphasize Cytotoxics

Executive Summary

Bristol-Myers Squibb is aiming to recapture its leadership in oncology by focusing on developing novel cytotoxic agents as well as concentrating on the emerging field of targeted therapies, Chief Scientific Officer Elliott Sigal said during a post-ASCO call

You may also be interested in...



Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication

Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications

Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication

Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications

Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol

With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients

Related Content

UsernamePublicRestriction

Register

PS047330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel